Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02908451 · ClinicalTrials.gov registry record · Phase 1
A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer
A Phase 1 study, sponsored by AbGenomics B.V Taiwan Branch.
- Terminated
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT02908451 is a Phase 1 study that was terminated before completion, run by AbGenomics B.V Taiwan Branch. The registered enrollment target is 39 participants.
The verdict
NCT02908451, a Phase 1 study, was terminated before completion, sponsored by AbGenomics B.V Taiwan Branch.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This study is to define the safety profile and to determine the Maximal tolerated dose regimen and preliminary efficacy of AbGn-107 administered every 14 days (Q2W regimen) or 28 days (Q4W regimen) in patients with chemo-refractory locally advanced, recurrent or metastatic gastric, colorectal, pancreatic or biliary cancer.
Interventions
- BIOLOGICAL AbGn-107
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2017-04-24 |
| Est. Completion | 2021-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02908451
The ClinicalTrials.gov registry entry for NCT02908451 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbGenomics B.V Taiwan Branch, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AbGn-107 is the first listed.
NCT02908451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02908451 about?
NCT02908451 is a clinical study titled "A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer". This study is to define the safety profile and to determine the Maximal tolerated dose regimen and preliminary efficacy of AbGn-107 administered every 14 days (Q2W regimen) or 28 days (Q4W regimen) in patients with chemo-refractory locally advanced, recurrent or metastatic gastric, colorectal, pancr...
What is the current status of trial NCT02908451?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2017-04-24. Estimated completion is 2021-02-28.
What interventions are being tested in trial NCT02908451?
The interventions under investigation include: AbGn-107 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02908451?
This trial is sponsored by AbGenomics B.V Taiwan Branch, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.